Skip to content
akaturk Academic measurement

Article detail · 2014

Tigecycline in the management of post neurosurgical spondylodiscitis a review of eight cases

YÖKSİS OpenAlex Open access · gold SJR Q1 JCR Q3 Citations 14 Percentile 80.6% FWCI 1.41
Year
2014
Type
article

Data source split

  • YÖKSİS YÖKSİS article record
  • YÖKSİS venue International Journal of Infectious Diseases
  • Catalog match (ISSN) International Journal of Infectious Diseases
  • OpenAlex OpenAlex enrichment (abstract, citations, topics)

Abstract

OpenAlex · English

BACKGROUND: Tigecycline is a relatively new glycylcycline antimicrobial, active in vitro against a variety of Gram-positive and Gram-negative organisms. In this study we evaluated the outcomes of spondylodiscitis cases treated with tigecycline-including therapies retrospectively. METHODS: All adult (age >18 years) cases with a diagnosis of spondylodiscitis, who were treated with a tigecycline-including therapy between 2007 and 2011, were included in the study. The primary efficacy outcome was clinical success with tigecycline at the end of induction, while the secondary efficacy outcome was maintenance of success through 3 months following completion of induction. RESULTS: A total of eight spondylodiscitis cases fulfilled the study inclusion criteria. All cases had back pain, restricted mobility, magnetic resonance findings associated with spondylodiscitis, and microbiology or pathological findings related to spondylodiscitis. All had post-neurosurgical spondylodiscitis. In five cases, tigecycline was started in accordance with the antibacterial susceptibility results from intervertebral tissue biopsy cultures, whereas in three it was started empirically. All cases had received several different antibacterials with failure before receiving tigecycline. The mean duration of tigecycline treatment was 37±21 days. One case was lost to follow-up after 2 days of tigecycline. Primary and secondary success was achieved in the remaining seven cases. CONCLUSIONS: These limited data suggest that tigecycline may have a role in the treatment of refractory spondylodiscitis cases.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

14 citations

OpenAlex cited_by_count (cache / database)

Authors

  1. OĞUZ REŞAT SİPAHİ
  2. Kahraman Hasip
  3. SİNAN MERMER
  4. HÜSNÜ PULLUKÇU
  5. MELTEM TAŞBAKAN EGE ÜNİVERSİTESİ
  6. BİLGİN ARDA
  7. TANSU YAMAZHAN
  8. TAŞKIN YURTSEVEN
  9. SABİRE ŞÖHRET AYDEMİR EGE ÜNİVERSİTESİ
  10. SERCAN ULUSOY